AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease

M. Ehrenfeld, M. Blank, Y. Shoenfeld, M. Hídvégi

Research output: Article

17 Citations (Scopus)

Abstract

The potential of oral treatment with AVEMAR (AVEMAR), a new benzoquinone-containing fermentation product of wheat germ, on features of experimental systemic lupus erythematosus (SLE) in naive mice, induced by idiotypic manipulation, was studied. We assessed the effect of AVEMAR on the profile of autoantibody production and the response of Th1/Th2 related cytokines as well as the clinical picture of experimental SLE in the SLE-induced mice. When the product was given in the pre-immunization period, down-regulation of autoantibody production (anti-dsDNA, mouse 16/6Id, and anti-histones) following treatment with AVEMAR was noted (eg anti-dsDNA decreased from 0.898±0.097 OD at 405 nm to 0.519±0.103 OD following treatment). This effect was sustained for at least 4 weeks after discontinuation of the therapy. Serological manifestations associated with a delay in Th2 response (IL-4 and IL-10) were recorded (eg IL-4 decreased from 91.7±8.11 to 59.55±7.78 ng/ml in splenocyte condition media). The mice showed normal ESR, WBC and less than 100mg/dl of protein in the urine in comparison to > 300 mg/dl protein in the SLE non-treated mice. In conclusion, oral intake of AVEMAR can ameliorate the clinical manifestations of experimental SLE, via affecting the Th1/Th2 network inhibiting Th2 response.

Original languageEnglish
Pages (from-to)622-627
Number of pages6
JournalLupus
Volume10
Issue number9
DOIs
Publication statusPublished - 2001

Fingerprint

Biological Products
Systemic Lupus Erythematosus
Interleukin-4
Autoantibodies
Therapeutics
Interleukin-10
Histones
Triticum
Fermentation
Immunization
Proteins
Down-Regulation
benzoquinone
Urine
Cytokines

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

@article{553b0f2b9a0c4bb5892c4c5c6cb42981,
title = "AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease",
abstract = "The potential of oral treatment with AVEMAR (AVEMAR), a new benzoquinone-containing fermentation product of wheat germ, on features of experimental systemic lupus erythematosus (SLE) in naive mice, induced by idiotypic manipulation, was studied. We assessed the effect of AVEMAR on the profile of autoantibody production and the response of Th1/Th2 related cytokines as well as the clinical picture of experimental SLE in the SLE-induced mice. When the product was given in the pre-immunization period, down-regulation of autoantibody production (anti-dsDNA, mouse 16/6Id, and anti-histones) following treatment with AVEMAR was noted (eg anti-dsDNA decreased from 0.898±0.097 OD at 405 nm to 0.519±0.103 OD following treatment). This effect was sustained for at least 4 weeks after discontinuation of the therapy. Serological manifestations associated with a delay in Th2 response (IL-4 and IL-10) were recorded (eg IL-4 decreased from 91.7±8.11 to 59.55±7.78 ng/ml in splenocyte condition media). The mice showed normal ESR, WBC and less than 100mg/dl of protein in the urine in comparison to > 300 mg/dl protein in the SLE non-treated mice. In conclusion, oral intake of AVEMAR can ameliorate the clinical manifestations of experimental SLE, via affecting the Th1/Th2 network inhibiting Th2 response.",
keywords = "Autoantibodies, AVEMAR, Benzoquinone, Cytokines, Experimental model, Wheat germ",
author = "M. Ehrenfeld and M. Blank and Y. Shoenfeld and M. H{\'i}dv{\'e}gi",
year = "2001",
doi = "10.1191/096120301682430203",
language = "English",
volume = "10",
pages = "622--627",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - AVEMAR (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease

AU - Ehrenfeld, M.

AU - Blank, M.

AU - Shoenfeld, Y.

AU - Hídvégi, M.

PY - 2001

Y1 - 2001

N2 - The potential of oral treatment with AVEMAR (AVEMAR), a new benzoquinone-containing fermentation product of wheat germ, on features of experimental systemic lupus erythematosus (SLE) in naive mice, induced by idiotypic manipulation, was studied. We assessed the effect of AVEMAR on the profile of autoantibody production and the response of Th1/Th2 related cytokines as well as the clinical picture of experimental SLE in the SLE-induced mice. When the product was given in the pre-immunization period, down-regulation of autoantibody production (anti-dsDNA, mouse 16/6Id, and anti-histones) following treatment with AVEMAR was noted (eg anti-dsDNA decreased from 0.898±0.097 OD at 405 nm to 0.519±0.103 OD following treatment). This effect was sustained for at least 4 weeks after discontinuation of the therapy. Serological manifestations associated with a delay in Th2 response (IL-4 and IL-10) were recorded (eg IL-4 decreased from 91.7±8.11 to 59.55±7.78 ng/ml in splenocyte condition media). The mice showed normal ESR, WBC and less than 100mg/dl of protein in the urine in comparison to > 300 mg/dl protein in the SLE non-treated mice. In conclusion, oral intake of AVEMAR can ameliorate the clinical manifestations of experimental SLE, via affecting the Th1/Th2 network inhibiting Th2 response.

AB - The potential of oral treatment with AVEMAR (AVEMAR), a new benzoquinone-containing fermentation product of wheat germ, on features of experimental systemic lupus erythematosus (SLE) in naive mice, induced by idiotypic manipulation, was studied. We assessed the effect of AVEMAR on the profile of autoantibody production and the response of Th1/Th2 related cytokines as well as the clinical picture of experimental SLE in the SLE-induced mice. When the product was given in the pre-immunization period, down-regulation of autoantibody production (anti-dsDNA, mouse 16/6Id, and anti-histones) following treatment with AVEMAR was noted (eg anti-dsDNA decreased from 0.898±0.097 OD at 405 nm to 0.519±0.103 OD following treatment). This effect was sustained for at least 4 weeks after discontinuation of the therapy. Serological manifestations associated with a delay in Th2 response (IL-4 and IL-10) were recorded (eg IL-4 decreased from 91.7±8.11 to 59.55±7.78 ng/ml in splenocyte condition media). The mice showed normal ESR, WBC and less than 100mg/dl of protein in the urine in comparison to > 300 mg/dl protein in the SLE non-treated mice. In conclusion, oral intake of AVEMAR can ameliorate the clinical manifestations of experimental SLE, via affecting the Th1/Th2 network inhibiting Th2 response.

KW - Autoantibodies

KW - AVEMAR

KW - Benzoquinone

KW - Cytokines

KW - Experimental model

KW - Wheat germ

UR - http://www.scopus.com/inward/record.url?scp=0034793642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034793642&partnerID=8YFLogxK

U2 - 10.1191/096120301682430203

DO - 10.1191/096120301682430203

M3 - Article

C2 - 11678450

AN - SCOPUS:0034793642

VL - 10

SP - 622

EP - 627

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 9

ER -